AAVantgarde Bio
Milan, Lombardy, Italy · Biotechnology, Genetics, Health Care
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors
Key facts
- Headquarters
- Milan, Lombardy, Italy
- Employees
- 48
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Private
- Website
- https://www.aavantgarde.com/en/
- Company page
Recent activity at AAVantgarde Bio
- : AAVantgarde secures $141m Series B funding to advance its gene therapies for inherited retinal diseases.
- : AAVantgarde Appoints Rasmus Holm-Jorgensen as Chief Financial Officer
- : AAVantgarde Names Jayashree Sahni as Chief Medical Officer
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
AAVantgarde Bio funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Series B | $141.0M |
Leadership
- Claudio Spera, Vice President of Medical Affairs, Ophthalmology
- Malcolm Horsley, Vice President Project Management and Information Technology
- Ioulietta Mulligan, VP Biometrics & Clinical Technologies
- Nina Kotsopoulou, Chief Technical Officer
- Jayashree Sahni, Chief Medical Officer
- Magdalena Blanco, Not Provided
- Fabrizio Comper, Innovator In Protein Engineering
- Cindy Nguyen, Head of Operations and Compliance
- James Mcphie, Sas Programmer
- Alberto Auricchio, Founder
- Tessa Verbanic Brandon, Director, Regulatory Affairs
Verified email and direct lines for AAVantgarde Bio’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
AAVantgarde Bio in the news
- AAVantgarde Bio receives IND clearance for AAVB-039 - Ophthalmology Times (Jul 17, 2025)
- FDA Approves AAVantgarde’s IND Application for Stargardt Gene Therapy - BioPharm International (Jul 17, 2025)
- AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081 - Ophthalmology Times (Nov 25, 2025)
- AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies - Ophthalmology Times (May 16, 2025)
- FDA grants fast track designation to AAVantgarde Bio for AAVB-039 - Ophthalmology Times (Aug 12, 2025)
- AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA - Ophthalmology Times (Oct 03, 2025)
Companies similar to AAVantgarde Bio
- Applied StemCell · Biotechnology, Genetics, Health Care, research, Therapeutics
- Takis S.r.l · Biotechnology, Health Care, research, Therapeutics
- MeiraGTx Holdings plc · Biotechnology, Genetics, Health Care, Therapeutics
- Genetix Biotherapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- Entos Pharmaceuticals · Biotechnology, Genetics, Health Care, Therapeutics
About AAVantgarde Bio: questions and answers
What does AAVantgarde Bio do?
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors
Where is AAVantgarde Bio headquartered?
AAVantgarde Bio is headquartered in Milan, Lombardy, Italy.
How many employees does AAVantgarde Bio have?
AAVantgarde Bio has about 48 employees.
Has AAVantgarde Bio raised funding?
Yes. Fundz has recorded 1 funding event for AAVantgarde Bio. The most recent, Series B of $141.0M, was in Nov 2025.
Who leads AAVantgarde Bio?
Claudio Spera is a Vice President of Medical Affairs, Ophthalmology at AAVantgarde Bio.
What is the latest news on AAVantgarde Bio?
On Nov 3, 2025, AAVantgarde secures $141m Series B funding to advance its gene therapies for inherited retinal diseases.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy